
The Wyden kratom investigation reaches its first hard date today. When Sen. Ron Wyden of Oregon, the ranking Democrat on the Senate Finance Committee, opened an inquiry on Aug. 5 into how federal decisions on kratom and flavored vaping products were reached, he asked three recipients — the Department of Health and Human Services, Oklahoma-based Botanic Tonics, and tobacco company Reynolds American — to hand over records by Aug. 31, 2026. That is today.
The deadline arrives at the end of an unusually consequential week for the industry it concerns. On Aug. 26 a DEA temporary scheduling order placed three concentrated kratom derivatives into Schedule I. Within days, the company that says it makes most of one of them destroyed roughly $10 million of inventory. Both stories are about the same question, approached from opposite ends: who decides which kratom products stay on shelves, and on what evidence.
🏛️ What the Wyden kratom investigation actually asks
Wyden’s letters, dated Aug. 3 and released two days later, went to HHS Secretary Robert F. Kennedy Jr., Botanic Tonics CEO Jerry Ross and Reynolds American President and CEO David Waterfield. The kratom portion centers on a conflict-of-interest question first surfaced in New York Times reporting: Secretary of Homeland Security Markwayne Mullin has publicly urged restrictions on concentrated 7-OH products while, according to that reporting, holding a financial stake in Botanic Tonics — a company selling a competing product — worth as much as $1 million.
Two things are worth stating plainly. First, that is an allegation drawn from reporting and disclosure filings, not a finding; no agency or court has concluded that Mullin’s advocacy was improper. Second, this is a ranking-member inquiry, not a committee-authorized investigation. It carries no subpoena power. Recipients may produce everything, produce some of it, negotiate a schedule, or decline outright, and the practical consequence of declining is a press release rather than a court order.
That is a real limit, and it is also the reason today matters. What the three recipients do with a request they are not compelled to answer is itself informative — and if documents do arrive, they would be the first look anyone outside the agencies gets at how the 7-OH decisions were assembled.
💰 Ten million dollars, destroyed at cost
The market side of the same week was blunter. Vince Sanders, owner of Kansas City-based CBD American Shaman, told the Missouri Independent that his company produces the majority of mitragynine pseudoindoxyl (MGPI) products sold nationwide, and that after learning the DEA order was coming his team destroyed about $10 million of product — a figure he specified was “at cost, not at retail value.” Sanders said the company never manufactured the MGM-15 and MGM-16 compounds also named in the order, calling them less studied and more potent.
The destruction was not voluntary generosity. Once a substance enters Schedule I, possessing commercial quantities without a DEA registration is itself an offense, so an unsold inventory becomes a liability on the effective date. American Shaman was already operating under state pressure: Missouri Attorney General Catherine Hanaway sued the company in March over its 7-OH line, and it agreed to suspend in-state sales.
⚖️ What the order covers — and what the Wyden kratom investigation cannot reach

The scheduling order sits outside the Wyden kratom investigation entirely — different agency, different legal track — but it is the concrete backdrop against which the document request will be read. The DEA was explicit that the action is aimed at “deliberately manufactured and concentrated opioid products, not traditional botanical kratom.” The order describes MGPI, MGM-15 and MGM-16 as chemical rearrangements or derivatives of 7-OH, produced by oxidizing mitragynine rather than occurring meaningfully in the leaf. It also notes the consumer-facing form these took: of 51 MGPI products surveyed online, 35 carried flavors such as berry, lemonade and watermelon, 32 used brightly colored packaging, and 76% were chewable tablets.
That packaging detail is why the carve-out held. The case for scheduling was built on products engineered to be palatable and potent, and the agency drew the line there rather than at the plant. Our earlier coverage of the DEA’s first kratom Schedule I order walks through the filing itself.
The unresolved edge is analytical. The order concedes that published literature has not established MGPI as a naturally occurring kratom alkaloid, while acknowledging open questions about whether trace amounts might turn up in botanical products through processing, storage or testing artifacts. DOJ said in its press release — but not in the order — that it will exercise enforcement discretion where only incidental trace amounts appear in an otherwise conventional botanical product. The American Kratom Association, which supports enforcement against the concentrates, filed suit in federal court in Washington seeking to get that assurance written down; we covered that lawsuit yesterday.
“Responsible kratom consumers and legitimate botanical kratom businesses should not be put at risk because trace-level chemistry is detected in otherwise traditional botanical kratom.”
— Mac Haddow, American Kratom Association
🔬 The researchers’ objection
Christopher McCurdy, a pharmacy professor at the University of Florida and one of the most-cited kratom researchers in the country, agrees these compounds should not be sold unsupervised at gas stations but disagrees with Schedule I as the instrument. His concern is displacement: prohibition of a named compound tends to push manufacturing toward undisclosed analogues, and buyers lose the labeling they had. He co-authored a recent study finding kratom-derived products are frequently mislabeled to begin with.
He raised a second, quieter cost. Schedule I placement makes research on these compounds substantially harder — registration, secured storage, protocol review. The compounds most in need of characterization become the hardest ones to characterize. That is a familiar trade-off in drug scheduling, and it is worth naming honestly even when the underlying enforcement decision is defensible.
🗺️ A footnote on the map
One detail in the Senate release is already out of date, and it illustrates how fast this file moves. Wyden’s Aug. 5 announcement says kratom is “banned in eight states,” citing an advocacy-group map. By the time the letters were public, North Dakota had banned kratom by executive order; on Aug. 28 Massachusetts placed every form of kratom in state Schedule I by emergency order, a step we covered when the ban took effect. Our own count stands at 11 banned jurisdictions, and the state legality map on our homepage is checked daily against statutes and agency orders rather than secondary trackers. If you are trying to work out what is legal where you live, start there rather than with a number in a press release — including ours.
📅 What to watch next
Three dates. Today, whether HHS, Botanic Tonics or Reynolds American produce anything to Senate Finance in the Wyden kratom investigation, and whether Wyden says so publicly. Sept. 2, when the North Dakota Legislature convenes a special session on two bills that would replace the governor’s blanket emergency ban with an age-21 limit, labeling rules and a synthetic-derivative schedule. And an open date: the separate DEA order on 7-OH itself, which as proposed would cover processed products above 0.05% 7-OH or 1 milligram per article, plus botanical material above 0.05% by dry weight. That last threshold is the one the botanical trade is watching, because it is the first federal number that would apply directly to leaf. Consumers comparing sellers can also check our kratom vendors directory for who publishes third-party lab results.
None of this changes the underlying health picture, which deserves stating alongside the policy: regular kratom use can cause physical dependence and withdrawal, and concentrated 7-OH and MGPI products carry meaningfully greater risk than traditional leaf. The most defensible thing in this week’s news may simply be that federal regulators drew their line at the concentrates and said so out loud — and that an industry association, a federal court and a Senate committee are all now testing whether that line holds where it was drawn.
❓ Frequently asked questions
What is the Wyden kratom investigation?
It is an inquiry opened on Aug. 5, 2026 by Sen. Ron Wyden of Oregon, the ranking Democrat on the Senate Finance Committee. Wyden sent letters dated Aug. 3 to HHS Secretary Robert F. Kennedy Jr., Botanic Tonics CEO Jerry Ross and Reynolds American President and CEO David Waterfield, asking for records about how federal decisions on kratom and flavored vaping products were made. Because it was opened by the ranking member rather than authorized by the full committee, it carries no subpoena power.
What is the August 31 deadline?
Wyden’s press release set Aug. 31, 2026 as the date by which the three recipients were asked to provide documents and answers to the committee. It is a request date, not a court-ordered one. Recipients can respond in full, respond in part, negotiate a rolling production, or decline.
Did the DEA ban all kratom?
No. The temporary scheduling order that took effect in late August covers three concentrated derivatives — mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16. The DEA stated the action targets “deliberately manufactured and concentrated opioid products, not traditional botanical kratom.” A separate proposed order covering 7-hydroxymitragynine above set thresholds has not been issued.
Why did American Shaman destroy $10 million of product?
Owner Vince Sanders told the Missouri Independent that his company produces most of the nation’s MGPI products and destroyed roughly $10 million of inventory — valued at cost, not retail — after learning the federal order was coming. Once a substance enters Schedule I, holding it without a registration is itself unlawful.
Is kratom addictive?
Regular use of kratom can produce physical dependence and a withdrawal syndrome on stopping, and concentrated 7-OH and MGPI products carry substantially higher risk than traditional leaf. Anyone using kratom daily, or considering stopping after heavy use, should talk to a clinician rather than taking a large dose down on their own.
📚 Sources
- U.S. Senate Committee on Finance — Wyden inquiry announcement and letters, Aug. 5, 2026
- Missouri Independent — “Missouri kratom company destroys $10M in products after DEA crackdown,” Aug. 28, 2026
- U.S. Department of Justice — emergency scheduling of three opioid compounds
- Federal Register public inspection — DEA temporary scheduling order (PDF)
- UF Health — study finds kratom-derived products frequently mislabeled
- KCUR — Kansas City kratom company destroys $10 million in products, Aug. 29, 2026
Not medical advice. Kratom News reports on law, policy and science. Nothing here is medical advice, and nothing here should be read as encouragement to start, continue or stop using kratom. Kratom can cause physical dependence and withdrawal, and concentrated derivative products carry higher risk than traditional leaf. Talk to a qualified clinician about your own situation. If you are struggling with substance use, the SAMHSA National Helpline is available at 1-800-662-4357.
